September 2016: Life Science Compliance Update
The full text of the entire issue is now available to our subscribers. If you are a subscriber please log in now. You may also buy this issue by clicking on the button below.
In this month’s issue of the Update, we literally span the compliance frontier. First, we focus on whether the OIG is giving medical device companies a break when it comes to enforcement. We then move on to transparency and an article by Nick Merryfield and Andrew Wiles comparing the Open Payments data for pharmaceuticals and medical devices. Given that it’s still transparency season, we also have any article by Geert van Gansewinkel of Polaris on European Transparency, and a look at FDA Clinical Investigator disclosures and Open Payments. Finally, Brian Dahl takes a look at the impact of shareholder actions triggered by enforcement actions.
At the Punishment Wheel: Are Medical Device Companies Getting Preferential Treatment?
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer for Life Science Compliance Update
Pharma & Medtech – Like Chalk & Cheese?
Nick Merryfield and Andrew Wiles of WorldDataOnline LLC.
State of the European Union – Transparency in Europe 2016 and Beyond
Geert van Gansewinkel, Partner and Managing Director, Polaris Europe
As If the DOJ Weren’t Enough – Shareholders Are Increasingly Quick to Sue to Recover Lost Value Triggered by Enforcement Actions
Brian A. Dahl
AseraCare – Even Courts Seek Second Medical Opinions
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update